A recent investigation by Puhr et al. [81] on GR expression and its functional significance in both prostate cancer cell lines and prostate cancer patients found that GR expression is low in primary prostate cancer tissue but is significantly increased during long-term exposure to enzalutamide. The gene discussed is NR3C1; the disease is prostate carcinoma.